跳至主要内容
临床试验/2025-525122-35-00
2025-525122-35-00招募中4 期

Attachment Development and Learning in ADHD: The Role of Dopamine.

UZ Leuven1 个研究点 分布在 1 个国家目标入组 64 人开始时间: 2026年10月1日最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
招募中
发起方
UZ Leuven
入组人数
64
试验地点
1
主要终点
Children’s instrumental responding to caregiver-related cues compared to neutral cues; children’s trust learning and support-seeking behavior; behavioral-based rating of children’s attachment representations and parental sensitivity; immediate affective relationship dynamics.

研究概览

简要总结

To investigate how methylphenidate (compared to placebo) influences attachment-related learning processes and behavior in children with ADHD.

入排标准

年龄范围
0 years 至 17 years(0-17 Years)
接受健康志愿者

入选标准

  • Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures.
  • Children aged 8-12 years, currently attending elementary school.
  • A prior diagnosis of ADHD, which is again confirmed in routine clinical care with a structured diagnostic interview (K-SADS; (Kaufman et al., 1997)) before the start of the PCT.
  • Initiation of pharmacological treatment with methylphenidate (MPH) within the past 0-12 months, in accordance with evidence-based Flemish/Dutch guidelines (Emmers et al., 2023; Zorgpad ADHD, n.d.), via a 5-week double-blind, placebo-controlled titration (PCT) procedure as implemented in routine clinical practice. During this PCT, the child was identified as a responder, and an optimal dose of short-acting MPH (SA-MPH) was established. Between completion of the PCT and study start, adjustments in dosage and/or formulation (e.g., switch to long-acting MPH) may have occurred, based on clinical evaluation of therapeutic (side) effects by the treating child psychiatrist at the ADHD clinic of UZ Leuven.
  • Fluency in Dutch of the child and its primary caregiver.

排除标准

  • Formal diagnosis of co-occurring autism spectrum disorder and/or major neurological disorders, as these conditions may involve distinct learning processes relating to attachment (Odent et al., 2021).
  • Use of non-stimulant psychopharmacological treatments (e.g., atomoxetine, antidepressants, antipsychotics, guanfacine, bupropion), with the exception of melatonin, to allow for a controlled comparison of attachment-related measures under stimulant medication versus no-medication conditions, without the potential confounding influence of other psychotropic agents.
  • Stimulant medication use (e.g., Ritalin, Equasym) less than 32 hours prior to testing at time points 1 or
  • Children will be asked to refrain from using stimulant medication for at least 32 hours before each testing session.
  • Current participation in any form of family therapy, mediation, or parenting program at the time of either testing session (T1 or T2), as such interventions may influence child and/or parent behavior and interaction patterns.
  • Participation in another interventional trial involving an investigational medicinal product (IMP) or device.
  • IQ below 70, as established through prior WISC-V-NL testing (David Wechsler, 2017).

结局指标

主要结局

Children’s instrumental responding to caregiver-related cues compared to neutral cues; children’s trust learning and support-seeking behavior; behavioral-based rating of children’s attachment representations and parental sensitivity; immediate affective relationship dynamics.

Children’s instrumental responding to caregiver-related cues compared to neutral cues; children’s trust learning and support-seeking behavior; behavioral-based rating of children’s attachment representations and parental sensitivity; immediate affective relationship dynamics.

次要结局

未报告次要终点

研究者

发起方
UZ Leuven
申办方类型
Hospital/Clinic/Other health care facility
责任方
Principal Investigator
主要研究者

Karen Vertessen

Scientific

UZ Leuven

研究点 (1)

Loading locations...

相似试验